Print
Email
Print Edition StoriesMonday, March 9, 2009
Merrimack Pharmaceuticals promotes Nielsen, Stewart
By Mass High Tech staff
MHT's Galen Moore: Charities score with online fundraising
MHT's Marc Songini: RI plans launch of cord blood center
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Merrimack Pharmaceuticals Inc. has appointed Ulrik Nielsen to the positions of senior vice president and chief scientific officer, and Edward Stewart to the role of senior vice president of business development.
A founder of Merrimack, Nielsen will continue to direct the strategic direction for research, products and projects within the company. Prior to helping to launch the company, he served as a post-doctoral fellow at MIT, conducting work in biology, engineering and computational biology. He graduated from the University of Copenhagen with a doctorate in molecular biology, as well as master’s and bachelor’s degrees in biochemistry.
An eight-year veteran of Merrimack, Stewart will continue in his new role to direct licensing, intellectual property management, corporate partnering and other business development responsibilities. Stewart graduated from Cornell University’s Johnson School with a master’s degree in business administration and from Bates College with a bachelor’s degree.
Merrimack develops a compound called MM-121, a human monoclonal antibody designed to block signaling of the particular receptor that plays a critical role in cancer signaling. MM-121 is the company’s first oncology product, officials said, and is the first selective antagonist for that receptor — ErbB3 — to enter human clinical development. Merrimack began its first Phase 1 study of the compound in August 2008.
The privately funded biotech firm, based in Cambridge, says its biologic drug discovery technology, invented by scientists from MIT and Harvard University, rapidly identifies proteins to improve validation.
RSS Feeds
Comments
Please Login/Register to post comments.
No comments have been added or approved.